| Manley, Geoffrey T |
APT-TBI-01, NCT05826912: Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury |
|
|
| Enrolling by invitation | 2 | 672 | US | Atorvastatin Calcium, ATOR, Minocycline Hydrochloride, MINO, Candesartan Cilexetil, CAND, Placebo | University of California, San Francisco, United States Department of Defense | Traumatic Brain Injury | 08/28 | 08/29 | | |
NCT04602806: Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1 |
|
|
| Completed | N/A | 50 | US | | University of California, San Francisco, U.S. Army Medical Research and Development Command | Traumatic Brain Injury | 11/22 | 01/23 | | |
| Hsue, Priscilla |
| Withdrawn | 3 | 550 | US | Baricitinib 4 MG, Olumiant, Placebo | Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University | Post-Acute COVID-19 Syndrome | 12/27 | 12/29 | | |
| Recruiting | 3 | 140 | US | Alirocumab, Sar236553/REG727, Placebo | University of California, San Francisco, Massachusetts General Hospital | Dyslipidemias, Cardiovascular Diseases, HIV Infections | 07/24 | 07/25 | | |
NCT02272946: Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk |
|
|
| Completed | 2 | 43 | US | Canakinumab, IL--1β, Placebo | Priscilla Hsue, MD, Massachusetts General Hospital | HIV, Cardiovascular Disease | 02/21 | 12/21 | | |
| Active, not recruiting | 2 | 40 | US | Ensitrelvir, ensitrelvir fumaric acid, Placebo | Timothy Henrich, Shionogi Inc. | Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19 | 06/25 | 12/25 | | |
NCT06029712: Heart Failure Polypill at a Safety Net Hospital |
|
|
| Active, not recruiting | 2 | 35 | US | Heart failure polypill, Control Rx | University of California, San Francisco, UCSF CAPS-HIV Innovative Grant, UCSF CFAR-ARI HIV Boost Award, ACC/ABC Merck Research Fellowship Award (support for Dr. DeJong) | Heart Failure With Reduced Ejection Fraction, HIV Infections | 09/24 | 12/24 | | |
| Active, not recruiting | 2 | 36 | US | AER002, Placebo | Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation | Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19 | 07/24 | 07/25 | | |
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial) |
|
|
| Recruiting | 2 | 121 | US | Bempedoic acid, BA, Placebo | Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital | Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis | 03/28 | 03/28 | | |
| Graf, Jonathan |
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA |
|
|
| Terminated | 3 | 196 | US | TC99m-tilmanocept, tilmanocept, Lymphoseek | Navidea Biopharmaceuticals | Rheumatoid Arthritis | 07/24 | 07/24 | | |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
| Carvidi, Alex |
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA |
|
|
| Terminated | 3 | 196 | US | TC99m-tilmanocept, tilmanocept, Lymphoseek | Navidea Biopharmaceuticals | Rheumatoid Arthritis | 07/24 | 07/24 | | |
NCT06201416: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis |
|
|
| Recruiting | 1 | 24 | US | SBT777101 | Sonoma Biotherapeutics, Inc. | Rheumatoid Arthritis | 03/26 | 03/26 | | |
